Holen Sie sich die Stockscreener-App
9.78
2.30%
0.22
Vorhandelsmarkt:
9.97
0.19
+1.94%
Schlusskurs vom Vortag:
$9.56
Offen:
$9.54
24-Stunden-Volumen:
1.09M
Relative Volume:
0.78
Marktkapitalisierung:
$592.57M
Einnahmen:
$217.11M
Nettoeinkommen (Verlust:
$-651.19M
KGV:
-0.7529
EPS:
-12.99
Netto-Cashflow:
$-387.26M
1W Leistung:
+8.55%
1M Leistung:
+11.52%
6M Leistung:
+15.06%
1J Leistung:
-11.33%
1-Tages-Spanne:
$9.34
$10.05
1-Wochen-Bereich:
$8.75
$10.05
52-Wochen-Spanne:
$5.00
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Vergleichen Sie DNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
9.78 | 579.24M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
Ginkgo Bioworks Partners With Deep Origin-Led Team on ARPA-H to Develop Drug Safety Platform - marketscreener.com
Ginkgo Bioworks Partners on Deep Origin-Led Team to Develop New Tools for Pred Predictive Drug Safety - marketscreener.com
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety - Finviz
Ginkgo Bioworks partners with Deep Origin on ARPA-H drug safety project - Investing.com UK
Ginkgo Bioworks (NYSE: DNA) to aid ARPA-H CATALYST drug safety modeling platform - Stock Titan
Ginkgo Bioworks (NYSE:DNA) Shares Gap UpWhat's Next? - MarketBeat
Ginkgo Bioworks to Hold Special Meeting of Shareholders - GuruFocus
Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform - Investing.com
Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform By Investing.com - Investing.com South Africa
Ginkgo Bioworks stock rises on $47M DOE contract award By Investing.com - Investing.com South Africa
Ginkgo Bioworks stock rises on $47M DOE contract award - Investing.com India
Ginkgo Bioworks Holdings Inc selected by PNNL to deliver a modular, high-throughput phenotyping platform for DOE's M2PC - marketscreener.com
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High-Throughput Phenotyping Platform for DOE's M2PC - Finviz
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC - marketscreener.com
Ginkgo Bioworks (NYSE: DNA) lands four-year, up to $47M PNNL automation deal - Stock Titan
Will Ginkgo Bioworks Holdings Inc. Class stock announce a stock splitCEO Change & AI Based Buy and Sell Signals - Newser
Is Ginkgo Bioworks Holdings Inc. stock a buy before product launchesMarket Rally & Consistent Growth Equity Picks - Newser
Ginkgo Bioworks Holdings, Inc. $DNA Holdings Boosted by Geode Capital Management LLC - MarketBeat
Ginkgo Bioworks Collaborates With Strm.Bio, Partners on ARPA-H Contract for Cell Engineering, Gene Therapy - marketscreener.com
STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy - Finviz
Ginkgo Bioworks (NYSE: DNA) partner STRM.BIO lands ARPA-H deal worth up to $8.4M - Stock Titan
Ginkgo Bioworks Holdings (DNA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What analysts say about Ginkgo Bioworks Holdings Inc stockMomentum Trading Signals & Low Cost Market Strategies - earlytimes.in
Ginkgo Bioworks Holdings, Inc. $DNA Position Lifted by Legal & General Group Plc - MarketBeat
Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions (PR Newswire) - Aktiellt
Retail Trends: Is Ginkgo Bioworks Holdings Inc. stock a contrarian buyJuly 2025 Drop Watch & Risk Managed Investment Signals - BỘ NỘI VỤ
Will Ginkgo Bioworks Holdings Inc. stock recover faster than marketJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - BỘ NỘI VỤ
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors (PR Newswire) - Aktiellt
(DNA) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How Ginkgo Bioworks Holdings Inc. Class stock compares with tech leaders2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - newser.com
How Ginkgo Bioworks Holdings Inc. Class stock benefits from digital adoptionStop Loss & Weekly High Potential Stock Alerts - newser.com
Will Ginkgo Bioworks (DNA) Leverage ARPA-H Partnership to Advance Its Oral Therapeutics Ambitions? - Yahoo Finance
Ginkgo Bioworks: Scaling Science, Not Revenue (NYSE:DNA) - Seeking Alpha
Is Ginkgo Bioworks Holdings Inc. Class stock resilient in recession scenarios - newser.com
Ginkgo Bioworks Holdings (DNA) Price Target Decreased by 11.11% to 10.88 - MSN
Ginkgo Bioworks Holdings Inc. stock daily chart insightsJuly 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Can Ginkgo Bioworks Holdings Inc. stock beat market expectations this quarter - newser.com
Will Ginkgo Bioworks Holdings Inc. stock gain from lower inflationWeekly Market Summary & Real-Time Price Movement Reports - newser.com
Is it time to cut losses on Ginkgo Bioworks Holdings Inc.Trade Exit Summary & AI Based Buy and Sell Signals - newser.com
Exit strategy if you’re trapped in Ginkgo Bioworks Holdings Inc.2025 Institutional Moves & Consistent Profit Trade Alerts - newser.com
Can Ginkgo Bioworks Holdings Inc. stock surprise with earnings upsideEarnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Published on: 2025-11-19 04:21:37 - newser.com
Madrona Venture Group LLC Makes New Investment in Ginkgo Bioworks Holdings, Inc. $DNA - MarketBeat
Will Ginkgo Bioworks Holdings Inc. Class stock deliver compounding returnsQuarterly Risk Review & Accurate Entry and Exit Point Alerts - newser.com
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):